X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
X4 Pharmaceuticals (XFOR) Misses Q1 EPS by 44c
May 6, 2021 8:25 AM EDTX4 Pharmaceuticals (NASDAQ: XFOR) reported Q1 EPS of ($1.30), $0.44 worse than the analyst estimate of ($0.86).
We are excited by the strong progress we have achieved to date in 2021 in the development of mavorixafor across multiple rare disease indications, said Paula Ragan, Ph.D., President and Chief... More
